Join to View Full Profile
1515 Holcolmb BlvdUnit 0072Houston, TX 77030
Phone+1 713-792-7030
Dr. Ok is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Hematopathology, 2012 - 2013
UMass Chan Medical SchoolResidency, Pathology-Anatomic and Clinical, 2008 - 2012
Yonsei University College of MedicineClass of 2004
Certifications & Licensure
TX State Medical License 2015 - 2025
MA State Medical License 2012 - 2017
American Board of Pathology Pathology - Anatomic/Pathology - Clinical- American Board of Pathology Clinical Informatics
- American Board of Pathology Pathology - Molecular Genetic
- American Board of Pathology Hematopathology
Publications & Presentations
PubMed
- Technical and Clinical Validity of Assessing Measurable Residual Disease by Multicolor Flow Cytometry in an Unselected Acute Myeloid Leukemia Patient Cohort.Sa A Wang, Shaoying Li, Wei Wang, Jie Xu, Beenu Thakral
Archives of Pathology & Laboratory Medicine. 2025-06-16 - 1 citationsDiffuse Large B-Cell Lymphoma/High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: A Study of 60 Cases.Do H Kim, L Jeffrey Medeiros, Jie Xu, Guilin Tang, Lianqun Qiu
Modern Pathology. 2025-05-01 - Phase 2 trial of ibrutinib in previously untreated high-risk smoldering mantle cell lymphoma.Charles Gaulin, Preetesh Jain, Ranjit Nair, Swaminathan P Iyer, Hun Ju Lee
Leukemia & Lymphoma. 2025-05-01
Journal Articles
- High-Grade B-cell Lymphomas with TdT Expression: A Diagnostic and Classification DilemmaChi Young Ok, L Jeffrey Medeiros, Sergej Konoplev, Nitin Jain, Elias Jabbour, Guilin Tang, Nature
Abstracts/Posters
- Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age _ 65 years) with Mantle C...Chi Young Ok, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma _ Cohort Study of 369 PatientsChi Young Ok, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age _ 65 years) with Mantle C...Chi Young Ok, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib E...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Clinical, Immunophenotypic and Genomic Findings  of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow P...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
